2d illustrations and photos/iStock via Getty Images OS Therapies ( OSTX ) has refiled to raise $8M through a proposed initial public offering. The oncology drug developer said in its most recent SEC filing that it was looking to offer 2M common shares priced at $4 per share. Underwriters would be granted a 45-day option to purchase up to 300K additional shares to cover any over-allotments.
Brookline Capital Markets is serving as bookrunner. OS Therapies hopes to list its shares on NYSE American under the symbol OSTX. Based in Maryland, OS Therapies is developing drugs for the treatment of bone cancer and other solid tumors.
The company’s lead asset, OST-HER2, is in Phase 2 testing for the treatment of osteosarcoma. OS Therapies filed a new S-1 on Thursday, just hours after pulling a prior S-1 filing that said it was looking to raise around $10M , with Boustead Securities serving as underwriter. More on OS Therapies Incorporated Financial information for OS Therapies Incorporated.
